All Stories

  1. Обзор исследований несуицидальных форм самоповреждений по шкалам и опросникам NSSI
  2. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
  3. Affective disorders in comorbidity with alcohol addiction: clinical and dynamic features, social adaptation level of patients
  4. Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
  5. Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
  6. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
  7. Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
  8. Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy
  9. Clinical value of comorbidity of affective disorders and alcohol dependence
  10. Incidence rate of anxiety and personality disorders and their interrelationship in senior-year students of the medical university
  11. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients
  12. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
  13. Доля наркозависимых среди завершённых суицидов
  14. Суицидальное поведение больных шизофренией с метаболическим синдромом
  15. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
  16. The difference in serum proteomes in schizophrenia and bipolar disorder
  17. Protective Effects of Pyruvic Acid Salt Against Lithium Toxicity and Oxidative Damage in Human Blood Mononuclear Cells
  18. Суицидальное и парасуицидальное рискованное поведение среди высокообразованной молодежи: дихотомия формирования и дифференцированные возможности когнитивно-поведенческой копинг-терапии
  19. Суицидальные действия наркозависимых: вопросы системного выявления и учёта
  20. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
  21. The Protective Action of Carnosine and Organic Lithium Salts against Ethanol-Induced Oxidative Damage of Blood Plasma Proteins and Lipids of Healthy Persons and Alcoholic Patients
  22. Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium
  23. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
  24. SIRT1 Allele Frequencies in Depressed Patients of European Descent in Russia
  25. Disorders of spatial working memory in affective disorders with mild current depression and their neurophysiological correlates
  26. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia
  27. Protective action of carnosine and organic lithium salts in case of ethanol-induced oxidative damage of proteins and lipids of blood plasma in healthy persons and alcoholic patients
  28. Time course of cognitive dysfunction and biochemical marker of CNS lesions S100ß in coronary artery bypass graft
  29. Связь суицидального поведения и безнадёжности с акатизией у больных шизофренией
  30. Суицидальное поведение больных биполярным аффективным расстройством при коморбидных психических заболеваниях
  31. IgG antibodies from the sera of patients degrade myelin basic protein
  32. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
  33. Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
  34. Depressive disorders in women of climacteric age (review of foreign literature for 2012–2016)
  35. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
  36. Inflammatory factors and immunophenotypes in adjustment disorders
  37. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine
  38. Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
  39. Olfaction, pain sensitivity and immunoendocrine system in substance use disorders
  40. Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders
  41. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics
  42. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders
  43. Association of polymorphic variants of PIP5K2A and HTR2C genes with response to antidepressant therapy of patients with a current depressive episode
  44. Association study of genetic markers of schizophrenia and its cognitive endophenotypes
  45. Gender aspects of medico-social adaptation in adults with early onset of epilepsy
  46. Indices of the antioxidant system and dopamine in blood plasma in the dynamics of microwave resonance therapy in patients with alcoholism
  47. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
  48. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group
  49. Agression of adolescents who comnmit offenses
  50. Cognitive functioning in alcoholic patients and efficiency of their correction with use of individualized therapy
  51. Therapeutic efficacy of original anticonvulsant meta-chloro-benzhydrylurea (m-ch-BHU) in the treatment of patients with a compulsive craving for alcohol
  52. not-labeling of psychiatry and mental patients
  53. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects
  54. Antioxidant and Immunotropic Properties of some Lithium Salts
  55. Treatment of Alcoholic Patients Using Anticonvulsant Urea Derivative Influences the Metabolism of Neuro-active Steroid Hormones - The System of Stress Markers
  56. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies
  57. The Effect of Chronic Alcohol Abuse on the Benzodiazepine Receptor System in Various Areas of the Human Brain
  58. An effect of quetiapine on the immune system of patients with schizophrenia
  59. Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease
  60. The association of the DRD3 gene with Parkinson’s disease
  61. The Influence of Alcohol Addiction on Cognitive Functions of the Representatives of Indigenous Population of Siberia
  62. An association of AKT1 gene polymorphism with antidepressant treatment response
  63. Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy
  64. Association of Cytokine Production with Hormone Level and Sensory Responses during the Formation of Psychoactive Drug Addiction in Men
  65. Влияние адамантилбромфениламина на параметры иммунитета и симптомы астении у пациентов с непсихотическими психическими расстройствами
  66. DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
  67. P.3.b.018 Gene polymorphisms of oxidative stress and glutamatergic system in schizophrenic patients with tardive dyskinesia
  68. Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age
  69. Ethnoterritorial Heterogeneity of Formation of Alcohol Dependence in Native Population of Siberia
  70. Cytochrome P450 System Activity in Alcoholic Patients From Different Ethnic Groups
  71. Brain-derived Neurotrophic Factor in Patients with Affective Disorders
  72. Use of Traditional and Atypical Neuroleptics in Therapy of Psychoses Caused by Use of Synthetic Drugs
  73. Serum Levels of Neurosteroids in Patients with Affective Disorders
  74. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility
  75. Analysis of alcohol dependence in indigenous peoples in Northern Siberia.
  76. Association between pathological olfaction, immunological abnormalities and predisposition to substance use
  77. Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
  78. P.2.a.008 Correlation between levels of Akt1/GSK-3β signaling pathway proteins and severity of depressive symptoms
  79. P.6.b.006 Carnosine protects blood plasma proteins from damaging effect of acetaldehyde
  80. Proteins of the Akt1/GSK-3β signaling pathway in peripheral blood mononuclear cells of patients with affective disorders
  81. Ratio of Antibodies to Neurotransmitters in the Serum of Students, Occasional Drug Users
  82. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
  83. Neurophysiological Patterns of Search and Creative Behavior in Patients with Psychoactive Substance-Induced Disorders
  84. Glutamate Concentration in the Serum of Patients with Schizophrenia
  85. Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics
  86. P.6.a.005 Density of thrombocyte benzodiazepine receptors and levels of neuroactive steroid hormones in alcoholic patients
  87. Features of EEG in patients with disorders due to psychoactive substance use during olfactory stimulation
  88. Psychological Defense and Strategies of Coping in Alcohol Dependence and Co-Dependence in Women
  89. 1579 – Migration and mental health of aborigines of siberia: new challenges of old problems
  90. 1581 – Steroid hormones levels in alcohol dependent patients under conditions of social isolation
  91. Conformational Stability of Leukocyte Lactate Dehydrogenase in Healthy Men of Different Age
  92. Neurosteroids Dehydroepiandrosterone and Its Sulfate in Individuals with Personality Disorders Convicted of Serious Violent Crimes
  93. P-14 - Dissociative mechanisms of formation of alcoholism in patients with co-morbid posttraumatic stress disorder
  94. Gender Heteronomy of the Formation of Heroin Addiction in Adolescents
  95. P.6.b.007 Influence of ethanol on synaptic benzodiazepine receptors and forming synapses in embryo's brain of alcoholic women
  96. P.6.008 Neuropeptide in treatment of alcoholism: effect on psychological functions and lymphocyte apoptosis
  97. P01-12 - Clinical prognosis of associated forms of alcoholism with co-morbid brain impairment
  98. P01-106 - Neuromorphologic and neurochemical regularities of prenatal exposure of developing human brain to alcohol
  99. P.6.a.007 Influence of neuroactive peptidic preparations on apoptosis of immunocompetent cells in alcoholic patients
  100. Spontaneous and In Vitro Induced Apoptosis of Lymphocytes and Neutrophils in Patients with Alcohol Dependence
  101. P02-80 - Steroid hormones in patients with personality disorders in conditions of social isolation
  102. PW01-218 - Apoptosis of lymphocytes in alcoholic patients during withdrawal syndrome therapy
  103. P.6.b.004 Apoptosis of immunocompetent cells in patients with alcoholism in dynamic of therapy
  104. Effects of Microwave Resonance Therapy on Erythrocyte and Plasma Proteins and Lipids in Alcoholics
  105. P.6.d.012 Immune system in opioid addicts
  106. P.6.b.003 Anticraving-therapy of alcoholism in patients with comorbid arterial hypertension: abilities of paroxetine
  107. Gender-associated patterns of heroin addiction in adolescents
  108. Comorbidity and therapy of affective disturbances in associated forms of alcoholism
  109. P.6.063 Clinical and biological effectiveness of anar therapy in opiate addicts
  110. P.1.045 Psychotropic drugs and homeostatic systems: Mechanism of psychoneuroimmunomodulation
  111. P.6.032 Pica, anxiety and addiction: Mechanismsand therapy
  112. Effect of carnosine on immunocompetent cells from alcoholic patients
  113. Immunity system in alcoholism
  115. Effects of antioxidant carnosine on immunity in addiction
  116. Therapeutic efficiency coaxil at treatment of alcoholism
  117. Efficacy of finlepsin-retard by alcoholism with comorbld brain impairment
  118. Olfaction, nociception and immunity in mental disorders
  119. Sensory systems and immunity in mental disorders